Enteris BioPharma Revenue and Competitors

Boonton, NJ

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Enteris BioPharma's estimated annual revenue is currently $1.2M per year.(i)
  • Enteris BioPharma's estimated revenue per employee is $77,500

Employee Data

  • Enteris BioPharma has 16 Employees.(i)
  • Enteris BioPharma grew their employee count by 7% last year.

Enteris BioPharma's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
CMOReveal Email/Phone
3
VP, Product Development & Quality ControlReveal Email/Phone
4
Director Quality AssuranceReveal Email/Phone
5
Quality Assurance ManagerReveal Email/Phone
6
QC ManagerReveal Email/Phone
7
Manager, Business DevelopmentReveal Email/Phone
8
Sr. Analytical Development ScientistReveal Email/Phone
9
Analytical ChemistReveal Email/Phone
10
Senior Production Manufacturing Tech IIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is Enteris BioPharma?

Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability. Enteris BioPharma’s internal clinical product pipeline consists of Ovarest® (oral leuprolide tablet), currently being evaluated in for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in aggregate. Additionally, Enteris BioPharma’s oral peptide delivery technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$1.2M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Enteris BioPharma News

2022-04-17 - Postmenopausal Osteoporosis market To Register Explosive ...

... Register Explosive Growth and Detailed Analysis by Top Manufactures: Amgen Inc., Clonz Biotech, Eli Lilly and Company, Enteris BioPharma.

2022-04-13 - Enteris BioPharma Announces Acceptance of Two Abstracts ...

BOONTON, N.J., April 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on...

2022-04-06 - Enteris BioPharma Highlighted as Game Changer in Drug ...

Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M1919%N/A
#2
$3.8M19-10%N/A
#3
$4.3M250%N/A
#4
$1.7M30-36%N/A
#5
$6.3M31-31%N/A